KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.

Can Cui, Sabrina Lin, Sarah Waliany, Meghanne Lomibao, Christina Falcon, Clare Wilhelm, Alexia Iasonos, Jessica J Lin, Alexander Drilon

J Thorac Oncol 104086

PMID42431264
PMCID-
DOI10.1016/j.jtho.2026.104086
发表日期2026-07-10
AI 判定该论文不进入自动 KM 提取:The record reports a secondary analysis of outcomes in subgroups of a larger Phase III trial (LIBRETTO-431), but it is not a report of the primary, randomized controlled comparison between the investigational and control arms. The abstract focuses on a comparison between chemoimmunotherapy and chemotherapy within the chemotherapy control arm, not the full randomized trial of selpercatinib versus chemotherapy. Therefore, it does not meet the criteria of reporting results of a human Phase III randomized controlled clinical trial.
摘要

摘要

BACKGROUND: Single-agent checkpoint inhibitor therapy achieves suboptimal outcomes in patients with advanced RET fusion-positive lung cancer. Prospective data on the role of adding checkpoint inhibitor therapy to platinum doublet chemotherapy has not previously been available. METHODS: In the registrational, phase 3 LIBRETTO-431 study, patients with RET fusion-positive lung cancer were randomized to receive selpercatinib or platinum-doublet chemotherapy (carboplatin/cisplatin and pemetrexed) with or without pembrolizumab. An analysis of outcomes including progression-free survival (PFS) and overall survival (OS) in patients treated with chemoimmunotherapy and chemotherapy alone was performed. RESULTS: Eighty-three patients received chemoimmunotherapy and nineteen patients received chemotherapy alone. No significant differences in smoking history (p=0.10), PD-L1 status (p=0.3), or baseline brain metastases (p=0.8) were identified between the two groups. The median PFS by blinded independent central review (BICR) was 11.2 months (95% confidence interval [CI]: 10.9-16.8) in chemoimmunotherapy-treated and not reached (95% CI: 4.9-not reached) in chemotherapy-treated patients. PFS by BICR was not significantly different (p=0.8) between chemoimmunotherapy- and chemotherapy-treated patients. The median OS was not reached for either group. OS did not significantly differ (p>0.9) between chemoimmunotherapy- and chemotherapy-treated patients. CONCLUSIONS: In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive NSCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。